Using clozapine to reduce violence in people with schizophrenia
4/7 Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
['FUNDING_R01'] · UNIVERSITY OF MARYLAND BALTIMORE · NIH-10873114
This study is looking at whether clozapine can help reduce violent behavior in people with schizophrenia, and it's for individuals who are at a higher risk of acting violently; participants will receive either clozapine or standard care over six months to see how it affects their behavior and mental health.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MARYLAND BALTIMORE (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-10873114 on ClinicalTrials.gov |
What this research studies
This research investigates the effectiveness of clozapine, an antipsychotic medication, in reducing the risk of violent behavior among individuals with schizophrenia. The study will involve a randomized clinical trial with 280 participants who are at high risk for violence, comparing clozapine treatment to standard care over a 24-week period. By collaborating across seven sites, the research aims to gather robust data that reflects real-world outpatient settings, addressing previous limitations in similar studies. Participants will be monitored for changes in violent behavior and overall mental health outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with schizophrenia who are considered at high risk for violent behavior.
Not a fit: Patients who do not have a diagnosis of schizophrenia or those who are not at risk for violent behavior may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for individuals with schizophrenia, potentially reducing violence and enhancing their quality of life.
How similar studies have performed: Previous studies have suggested that clozapine may be more effective than other antipsychotics in reducing aggression, but this research aims to provide more definitive evidence through a rigorous clinical trial.
Where this research is happening
BALTIMORE, UNITED STATES
- UNIVERSITY OF MARYLAND BALTIMORE — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KELLY, DEANNA L — UNIVERSITY OF MARYLAND BALTIMORE
- Study coordinator: KELLY, DEANNA L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.